Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model

Nature Cell Biology

Volumn 14, Issue 3, 2012, Pages 257-265

  Xia, Yifeng ^a   Yeddula, Narayana ^a   Leblanc, Mathias ^a   Ke, Eugene ^a,b   Zhang, Yonghui ^c   Oldfield, Eric ^c   Shaw, Reuben J ^a,d   Verma, Inder M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEFICIENCY; GENE; GENE TARGETING; IKBKB GENE; LUNG ALVEOLUS EPITHELIUM; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TIMP1 GENE; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD63; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHENYLAMINE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS P21(RAS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR BURDEN;

EID: 84862778064     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2428     Document Type: Article

References (50)

1. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 441, 431-436 (2006). (Pubitemid 44050137)
2. Barbie, D. A. et al. Systematic RNA inte-rference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
3. Basseres, D. S., Ebbs, A., Levantini, E. & Baldwin, A. S. Requirement of the NF-κB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 70, 3537-3546 (2010).
4. Meylan, E. et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104-107 (2009).
5. Takahashi, H., Ogata, H., Nishigaki, R., Broide, D. H. & Karin, M. Tobacco smoke promotes lung tumorigenesis by triggering IKKβ-and JNK1-dependent inflammation. Cancer Cell 17, 89-97 (2010).
6. Bivona, T. G. et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471, 523-526 (2011).
7. Karin, M., Yamamoto, Y. & Wang, Q. M. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3, 17-26 (2004). (Pubitemid 38088695)
8. Baud, V. & Karin, M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8, 33-40 (2009).
9. Li, Q. & Verma, I. M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734 (2002).
10. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. New Engl. J. Med. 359, 1367-1380 (2008).
11. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
12. Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer 7, 654-658 (2007).
13. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
14. Sutherland, K. D. & Berns, A. Cell of origin of lung cancer. Mol. Oncol. 4, 397-403 (2010).
15. Kim, C. F. et al. Mouse models of human non-small-cell lung cancer: raising the bar. Cold Spring Harb. Symp. Quant. Biol. 70, 241-250 (2005). (Pubitemid 44124878)
16. Meuwissen, R. Mouse models for human lung cancer. Genes Dev. 19, 643-664 (2005). (Pubitemid 40395076)
17. Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H. & Verma, I. M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17, 314-317 (1997). (Pubitemid 27475995)
18. Jackson, E. L. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001). (Pubitemid 34008190)
19. Aljada, I. S. et al. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J. Clin. Oncol. 22, 3218-3229 (2004). (Pubitemid 41103676)
20. Fong, K. M., Kida, Y., Zimmerman, P. V. & Smith, P. J. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin. Cancer Res. 2, 1369-1372 (1996). (Pubitemid 26299436)
21. Fleming, R. E. et al. Carbonic anhydrase II expression in rat type II pneumocytes. Am. J. Respir. Cell. Mol. Biol. 10, 499-505 (1994).
22. Jackson, E. L. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288 (2005). (Pubitemid 41743720)
23. Rekhtman, N. Neuroendocrine tumors of the lung: an update. Arch. Pathol. Lab. Med. 134, 1628-1638 (2010).
24. Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572-575 (2010).
25. Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567-571 (2010).
26. Tang, X. et al. Nuclear factor-κB (NF-κB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107, 2637-2646 (2006). (Pubitemid 44845619)
27. Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621-663 (2000). (Pubitemid 30365393)
28. Janssens, S. & Tschopp, J. Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ. 13, 773-784 (2006).
29. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444 (2008).
30. Thomas, P., Khokha, R., Shepherd, F. A., Feld, R. & Tsao, M. S. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol. 190, 150-156 (2000). (Pubitemid 30082487)
31. Stetler-Stevenson, W. G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal. 1, re6 (2008).
32. Wilczynska, K. M. et al. A novel mechanism of tissue inhibitor of metalloproteinases-1 activation by interleukin-1 in primary human astrocytes. J. Biol. Chem. 281, 34955-34964 (2006). (Pubitemid 46036534)
33. Jiang, Y., Goldberg, I. D. & Shi, Y. E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21, 2245-2252 (2002). (Pubitemid 34311378)
34. Jung, K. K., Liu, X. W., Chirco, R., Fridman, R. & Kim, H. R. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell su-rface protein. EMBO J. 25, 3934-3942 (2006). (Pubitemid 44338736)
35. Podolin, P. L. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Therapeut. 312, 373-381 (2004). (Pubitemid 40096491)
36. Birrell, M. A. et al. IκB kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am. J. Respir. Crit. Care Med. 172, 962-971 (2005). (Pubitemid 41476532)
37. Blasco, R. B. et al. c-Raf, but not B-Raf, is essential for development of K-ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19, 652-663 (2011).
38. Greten, F. R. et al. NF-κB is a negative regulator of IL-1βsecretion as revealed by genetic and pharmacological inhibition of IKKβ;. Cell 130, 918-931 (2007). (Pubitemid 47332565)
39. Nguyen, Q. et al. Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. Biochemistry 33, 2089-2095 (1994). (Pubitemid 24099604)
40. Pasparakis, M. et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417, 861-866 (2002). (Pubitemid 34670334)
41. Safran, M. et al. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol. Imaging 2, 297-302 (2003).
42. Tiscornia, G., Singer, O. & Verma, I. M. Production and purification of lentiviral vectors. Nat. Protoc. 1, 241-245 (2006).
43. Naka, S. et al. Activation of human CAII gene promoter by v-Src: existence of Ras-dependent and-independent pathways. Biochem. Biophys. Res. Commun. 272, 808-815 (2000). (Pubitemid 30420719)
44. Rankin, J. A. et al. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc. Natl Acad. Sci. USA 93, 7821-7825 (1996). (Pubitemid 26277122)
45. DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protocol. 4, 1064-1072 (2009).
46. Sweet-Cordero, A. et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 37, 48-55 (2005). (Pubitemid 40070939)
47. Baldi, P. & Long, A. D. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 17, 509-519 (2001). (Pubitemid 32600497)
48. Mootha, V. K. et al. PGC-1αresponsive genes involved in oxidative phospho-rylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003). (Pubitemid 36792858)
49. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005). (Pubitemid 41528093)
50. Pavlidis, P. & Noble, W. S. Matrix2png: a utility for visualizing matrix data. Bioinformatics 19, 295-296 (2003). (Pubitemid 36181920)